1337918-83-8
Chemical Structure
Vazegepant
Synonym(s): Zavegepant; BHV-3500
- CAS No.: 1337918-83-8
- Formula:C36H46N8O3
- Molecular Weight:638.80
IUPAC Name: (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
InChIKey: JJVAPHYEOZSKJZ-JGCGQSQUSA-N
SMILES: O=C(N1CCC(C2=CC3=C(NC2=O)C=CC=C3)CC1)N[C@H](CC4=CC5=C(NN=C5)C(C)=C4)C(N6CCN(C7CCN(C)CC7)CC6)=O
Biological Activity: Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist. Vazegepant can be used in the study of migraine[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vazegepant | 99.54% | Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist. Vazegepant can be used in the study of migraine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Vazegepant-13C,d3 | (Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020 Jun;33(3):309-315. [Content Brief]
- [2]. Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. [Content Brief]
- [3]. Capi M, De Angelis V, De Bernardini D, et al. Zavegepant[M]//Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing, 2022: 67-72.
- [4]. Jéssica Barreto Ribeiro Dos Santos, et al. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Eur J Pharmacol.2022 May 5:922:174902. [Content Brief]
Keywords
